Synergistic anti-neoplastic effect of AG1478 in combination with cisplatin or paclitaxel on human endometrial and ovarian cancer cells

Molecular Medicine Reports

Volumn 3, Issue 3, 2010, Pages 479-484

  Takai, Noriyuki ^a   Ueda, Tami ^a   Nishida, Masakazu ^a   Nasu, Kaei ^a   Narahara, Hisashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Endometrial cancer; Epidermal growth factor receptor; Ovarian cancer

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CISPLATIN; LIPOCORTIN 5; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL VIABILITY; CHEMICAL STRUCTURE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRION; OVARY CANCER;

EID: 77952372113     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000284     Document Type: Article

References (25)

1. Reinhardt MJ: Gynecologic tumors. Recent Results Cancer Res 170: 141-150, 2008.
2. Obel JC, Friberg G and Fleming GF: Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol 4: 459-468, 2006.
3. Winter WE III, Maxwell GL, Tian C, et al: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol 26: 83-89, 2008.
4. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
5. Hiraishi Y, Wada T, Nakatani K, et al: Immunohistochemical expression of EGFRand p-EGFRin oral squamous cell carcinomas. Pathol Oncol Res 12: 87-91, 2006. (Pubitemid 44197175)
6. Huang SM and Harari PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 17: 259-269, 1999.
7. Prenzel N, Fischer OM, Streit S, et al: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8: 11-31, 2001. (Pubitemid 32520251)
8. Kim SH, Song YC, Kim SH, Jo H and Song YS: Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells. Ann NY Acad Sci 1171: 642-648, 2009.
9. Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, et al: Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J Pharmacol Exp Ther 290: 1442-1457, 1999.
10. Zhao S, Chen X, Lu X, Yu Y and Feng Y: Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma. Gynecol Oncol 105: 45-54, 2007. (Pubitemid 46441469)
11. Arbel R, Rojansky N, Klein BY, Levitzki R, Hartzstark Z, Laufer N and Ben-Bassat H: Inhibitors that target protein kinases for the treatment of ovarian carcinoma. Am J Obstet Gynecol 188: 1283-1290, 2003.
12. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: Beta- hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol 109: 107-114, 2008.
13. Hirsch T, Marchetti P, Susin SA, et al: The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene 15: 1573-1581, 1997.
14. Marmor MD, Skaria KB and Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Rad Oncol Biol Phys 58: 903-913, 2004.
15. Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. J Cell Sci 117: 4619-4628, 2004.
16. Brader S and Eccles SA: Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90: 2-8, 2004.
17. Jing N and Tweardy DJ: Targeting Stat3 in cancer therapy. Anti-Cancer Drugs 16: 601-607, 2005.
18. Gao SP and Bromberg JF: Touched and moved by STAT3. Sci STKE 2006: 30, 2006.
19. Gibbs JB: Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest 105: 9-13, 2000.
20. Levitzki Aand Mishani E: Tyrphostins and other tyrosine kinase inhibitors. Ann Rev Biochem 75: 93-109, 2006. (Pubitemid 44118027)
21. Ellis AG, Doherty MM, Walker F, et al: Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 71: 1422-1434, 2006.
22. Chen Z, Zhang X, Li M, et al: Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 5930-5939, 2004.
23. El-Marjou A, Delouvee A, Thiery JP, et al: Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumor progression. Carcinogenesis 21: 2211-2218, 2000. (Pubitemid 32049227)
24. Wakeling AE: Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol 2: 382-387, 2002.
25. Nagane M, Narita Y, Mishima K, et al: Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95: 472-479, 2001.